Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Janssen Research & Development, LLC
Mayo Clinic
Janssen Research & Development, LLC
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
Stanford University
OHSU Knight Cancer Institute
Incyte Corporation
University of Washington
Incyte Corporation
Big Ten Cancer Research Consortium
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
University of California, San Diego
University of Chicago
Massachusetts General Hospital
M.D. Anderson Cancer Center
Baptist Health South Florida
Ohio State University Comprehensive Cancer Center
Columbia University
St. Petersburg State Pavlov Medical University
University of Zurich
M.D. Anderson Cancer Center
Baylor Research Institute
University of Chicago
City of Hope Medical Center
Ryvu Therapeutics SA
Princess Maxima Center for Pediatric Oncology
Oncotherapeutics
Oncotherapeutics
University of Birmingham
Institute of Hematology & Blood Diseases Hospital, China
St. Petersburg State Pavlov Medical University
Oncotherapeutics